Cargando…

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks

EGFR-type receptor tyrosine kinases achieve a broad spectrum of cellular responses by utilizing a set of structurally conserved building blocks. Based on available crystal structures and biochemical information, significant new insights have emerged into modes of receptor control, its deregulation i...

Descripción completa

Detalles Bibliográficos
Autor principal: Landgraf, Ralf
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851388/
https://www.ncbi.nlm.nih.gov/pubmed/17274834
http://dx.doi.org/10.1186/bcr1633
_version_ 1782132964757340160
author Landgraf, Ralf
author_facet Landgraf, Ralf
author_sort Landgraf, Ralf
collection PubMed
description EGFR-type receptor tyrosine kinases achieve a broad spectrum of cellular responses by utilizing a set of structurally conserved building blocks. Based on available crystal structures and biochemical information, significant new insights have emerged into modes of receptor control, its deregulation in cancer, and the nuances that differentiate the four human receptors. This review gives an overview of current models of the control of receptor activity with a special emphasis on HER2 and HER3.
format Text
id pubmed-1851388
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18513882007-04-12 HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks Landgraf, Ralf Breast Cancer Res Review EGFR-type receptor tyrosine kinases achieve a broad spectrum of cellular responses by utilizing a set of structurally conserved building blocks. Based on available crystal structures and biochemical information, significant new insights have emerged into modes of receptor control, its deregulation in cancer, and the nuances that differentiate the four human receptors. This review gives an overview of current models of the control of receptor activity with a special emphasis on HER2 and HER3. BioMed Central 2007 2007-01-22 /pmc/articles/PMC1851388/ /pubmed/17274834 http://dx.doi.org/10.1186/bcr1633 Text en Copyright © 2007 BioMed Central Ltd
spellingShingle Review
Landgraf, Ralf
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
title HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
title_full HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
title_fullStr HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
title_full_unstemmed HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
title_short HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
title_sort her2 therapy. her2 (erbb2): functional diversity from structurally conserved building blocks
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851388/
https://www.ncbi.nlm.nih.gov/pubmed/17274834
http://dx.doi.org/10.1186/bcr1633
work_keys_str_mv AT landgrafralf her2therapyher2erbb2functionaldiversityfromstructurallyconservedbuildingblocks